Anika Therapeutics (NASDAQ:ANIK) will post its quarterly earnings results after the market closes on Thursday, February 21st. Analysts expect Anika Therapeutics to post earnings of $0.35 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
Shares of ANIK opened at $38.93 on Thursday. Anika Therapeutics has a 12-month low of $28.54 and a 12-month high of $61.46. The stock has a market capitalization of $549.90 million, a P/E ratio of 19.86, a PEG ratio of 2.39 and a beta of 1.56.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. BidaskClub raised shares of Anika Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 25th. Finally, ValuEngine cut shares of Anika Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. Anika Therapeutics currently has an average rating of “Hold” and a consensus price target of $41.00.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.
See Also: Stochastic Momentum Index (SMI)
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.